$0.95
+0.04 (+4.38%)
Open$0.93
Previous Close$0.91
Day High$1.00
Day Low$0.88
52W High$1.84
52W Low$0.77
Volume—
Avg Volume143.0K
Market Cap15.18M
P/E Ratio—
EPS$-0.79
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,315.8% upside
Current
$0.95
$0.95
Target
$32.58
$32.58
$17.80
$32.58 avg
$40.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 354.8K | 2.19M | 1.96M |
| Net Income | -12,427,866 | -647,190 | -493,473 |
| Profit Margin | -3,509.7% | -29.6% | -25.2% |
| EBITDA | -13,947,340 | -712,204 | -583,546 |
| Free Cash Flow | — | -781,686 | -525,232 |
| Rev Growth | — | +18.0% | +10.8% |
| Debt/Equity | 0.14 | 0.28 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |